SR-TAC

SR-TAC (Sustained-Release Tacrolimus) is a long-acting, subcutaneous injectable formulation of the immunosuppressant tacrolimus, developed by Auritec Pharmaceuticals. It utilizes Auritec's proprietary Plexis technology, which coats the active ingredient, tacrolimus monohydrate, with a biocompatible polymer to achieve sustained drug release over a 30-day period. Primarily indicated for the prophylaxis of organ transplant rejection, SR-TAC is designed to address common issues with daily oral tacrolimus therapies, such as poor medication adherence, high intra-patient variability, and dose-related toxicity. As a calcineurin inhibitor, tacrolimus prevents the activation of T-lymphocytes by inhibiting the phosphatase activity of calcineurin. The formulation has undergone Phase 1 clinical testing to assess its safety and pharmacokinetic profile in healthy volunteers.

Other names

Sustained-Release TacrolimusSustained-Release Injectable Tacrolimus1-Month Sustained-Release Injectable Tacrolimustacrolimus monohydrate